ImClone Systems Corporation
New York, NY United States

Company Description

ImClone Systems wants to create identically successful cancer drug candidates. The company, a subsidiary of Eli Lilly, is focused on the development of oncology-related antibody therapies. The biotech research firm's only commercial product, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb (BMS) in North America and with Merck KGaA elsewhere. The company is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. It also has other potential oncology treatments in development.

180 Varick St.	Phone: 212-645-1405	http://www.imclone.com
New York, NY 10014	Fax: 212-645-2054	Map This Company
United States

Try a Full Premium Subscription

Access over 85 million companies
Call (866) 443-3939 or

ImClone Systems Corporation Rankings

Executives

41 executives listed for ImClone Systems Corporation's New York, NY location.
President	Bernhard Ehmer	E-mail
SVP Biopharmaceutical Operations	Richard Crowley	E-mail

More ImClone Systems Corporation Executives

Financials

Company Type	SubsidiaryHeadquarters
Fiscal Year-End	December
Employees	1,128

DNBi

Leverage D&B's credit assessment tools to positively impact
your business. Get the scoop on ImClone Systems Corporation now.

Reduce risk.
Drive greater profitability.
Increase cash flow.

ImClone Systems CorporationNew York, NY United States